drugset

drugset / Trial / NCT00274131

Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

NCT00274131 ↗

Phase 3 Completed 170 enrolled Boehringer Ingelheim

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of long-term treatment with pramipexole tablets (BI Sifrol®) in Parkinson's disease (phase III study).

Timeline

Start: 1998-12
Primary completion: —
Completion: 2004-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pramipexole	Unknown	1.5 mg	—

Indications